Press release
Non-Hodgkin Lymphoma Market (2026) | R&D Investments, Non-Hodgkin Lymphoma Therapeutics, T-cell Lymphoma, PI3 Kinase Inhibitor & Market Trends
Non-Hodgkin Lymphoma Market Size 2026
Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/non-hodgkin-lymphoma-market?kb
United States: Recent Industry Developments May 2026 to Jan 2026
✅ March 2026: Bristol Myers Squibb expanded clinical development activities for advanced CAR-T cell therapies targeting relapsed and refractory non-Hodgkin lymphoma patients.
✅ February 2026: Roche strengthened its hematology oncology portfolio through expanded research initiatives focused on precision therapies for B-cell non-Hodgkin lymphoma.
✅ January 2026: Gilead Sciences advanced manufacturing capabilities for cell therapies used in aggressive lymphoma treatment across U.S. oncology centers.
✅ December 2025: Pfizer increased investment in antibody-based oncology research programs focused on improving treatment outcomes for non-Hodgkin lymphoma patients.
Download Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/non-hodgkin-lymphoma-market?kb
List of Key Players 2026:
AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd
Key Strategic Growth Forecast Projections 2026:
The Global Non-Hodgkin Lymphoma Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: BeOne Medicines received U.S. FDA approval for BEQALZITM (sonrotoclax), becoming the first and only BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma (MCL).
✅ April 2026: Gilead Sciences' Tecartus® (brexucabtagene autoleucel) received full FDA approval for relapsed or refractory mantle cell lymphoma following positive confirmatory ZUMA-2 trial data.
✅ March 2026: Marker Therapeutics reported encouraging Phase 1 APOLLO trial data for MT-601, demonstrating strong objective response rates in relapsed Non-Hodgkin lymphoma patients.
✅ February 2026: Caribou Biosciences presented updated clinical data for vispa-cel (CB-010), highlighting durable efficacy in relapsed or refractory B-cell Non-Hodgkin lymphoma.
✅ January 2026: Incyte announced positive late-stage trial results for tafasitamab combination therapy in diffuse large B-cell lymphoma (DLBCL), showing improved progression-free survival outcomes.
✅ January 2026: ImmunityBio reported durable complete response data for its chemotherapy-free CD19 CAR-NK therapy in Waldenström Non-Hodgkin lymphoma patients.
✅ October 2025: Biopharmaceutical companies accelerated investments in next-generation CAR-T, CAR-NK, and targeted immunotherapies to improve treatment durability, safety, and patient outcomes across aggressive lymphoma indications.
How Our Market Research Process Works:
The global Non-Hodgkin Lymphoma Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Non-Hodgkin Lymphoma adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: Zydus Lifesciences agreed to acquire U.S.-based Assertio Holdings for USD 166.4 million, expanding its oncology supportive-care portfolio relevant to lymphoma treatment markets.
• May 2026: Zydus Lifesciences entered advanced talks to acquire a U.S. oncology drug maker valued between USD 100-150 million to strengthen its cancer therapeutics business.
• March 2026: Merck announced the acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline, including hematologic cancer programs linked to Non-Hodgkin lymphoma research.
• February 2026: Amgen agreed to acquire Dark Blue Therapeutics in a deal worth up to USD 840 million, adding blood cancer therapy assets to its oncology pipeline.
• March 2026: Roquefort Therapeutics signed a £32 million reverse takeover deal to acquire global rights to oncology drug AO-252 from Coiled Therapeutics for cancer treatment expansion
Request Strategic Market Customization: https://datamintelligence.com/customize/non-hodgkin-lymphoma-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company expanded oncology research collaborations focused on next-generation therapies for non-Hodgkin lymphoma treatment.
✅ February 2026: Chugai Pharmaceutical advanced clinical studies evaluating targeted monoclonal antibody therapies for lymphoma management.
✅ January 2026: Daiichi Sankyo strengthened hematologic cancer research initiatives supporting innovative treatment approaches for non-Hodgkin lymphoma.
✅ December 2025: Ono Pharmaceutical enhanced development activities for immuno-oncology therapies targeting relapsed lymphoma indications.
Major Segments Opportunity 2026:
By Disease Type: B-cell Lymphomas, T-cell Lymphoma
By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy
By Route of Administration: Oral, Parenteral, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regional Growth Intelligence for Market:
⇥ North America - Leads the Non-Hodgkin Lymphoma market due to advanced oncology treatment availability, strong healthcare infrastructure, and increasing adoption of targeted therapies.
⇥ Europe - Growth is supported by rising cancer awareness, expanding access to immunotherapy, and favorable reimbursement policies.
⇥ Asia-Pacific - Fastest-growing region driven by improving healthcare facilities, increasing cancer diagnosis rates, and growing investment in oncology care.
⇥ Latin America - Market expansion is influenced by improving access to cancer treatments and increasing healthcare expenditure.
⇥ Middle East & Africa - Emerging growth supported by expanding oncology services, healthcare modernization, and rising awareness of hematologic cancers.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=non-hodgkin-lymphoma-market?kb
Market Drivers 2026:
Rapid advancements in CAR-T cell therapy platforms improving treatment response rates for relapsed and aggressive Non-Hodgkin Lymphoma cases.
Increasing development of bispecific antibodies and next-generation immunotherapies expanding the oncology treatment landscape.
Growing focus on biomarker-guided therapies and genomic profiling supporting precision oncology strategies in lymphoma treatment.
Expansion of clinical trials evaluating combination therapies involving immunotherapy, chemotherapy, and targeted agents across multiple lymphoma subtypes.
Strategic collaborations among pharmaceutical companies, biotechnology firms, and cancer research institutes strengthening oncology drug development pipelines.
Continuous innovation in cell therapy manufacturing and biologics production improving scalability and treatment accessibility.
Increasing adoption of AI-supported diagnostic tools and digital pathology technologies enhancing lymphoma detection and treatment planning.
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Hodgkin Lymphoma Market (2026) | R&D Investments, Non-Hodgkin Lymphoma Therapeutics, T-cell Lymphoma, PI3 Kinase Inhibitor & Market Trends here
News-ID: 4513159 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Sickle Cell Disease Treatment Market to Reach USD 9.97 Billion by 2033 at 14.8% …
The global sickle cell disease treatment market was valued at USD 3.43 billion in 2025 and is projected to reach nearly USD 9.97 billion by 2033, growing at a CAGR of 14.8% during the forecast period from 2026 to 2033, according to a DataM Intelligence report. The market is experiencing strong growth driven by the rising global burden of sickle cell disease, increasing awareness regarding early diagnosis and disease management,…
Early Life Nutrition Market (2026-2033) | Organic Infant Formula, Probiotics, Ba …
DataM Intelligence has unveiled its latest research study, "Early Life Nutrition Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry expansion. It also highlights emerging opportunities,…
Middle East and North Africa Geographic Information System (GIS) Market (2026) | …
DataM Intelligence has unveiled its latest research study, "Middle East and North Africa Geographic Information System (GIS) Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry…
Pneumothorax Treatment Market to Reach USD 2.36 Billion by 2033 at 6.8% CAGR; No …
The global pneumothorax treatment market was valued at USD 1.48 billion in 2025 and is projected to reach nearly USD 2.36 billion by 2033, growing at a CAGR of 6.8% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of respiratory disorders, rising incidence of traumatic chest injuries, and growing demand for minimally invasive thoracic treatment procedures. Expanding adoption of…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
